^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NM21-1480
i
Other names: NM21-1480, ND021, PD-L1/4-1BB/HSA trispecific scDb-scFv , CS2006
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CStone Pharma, Numab
Drug class:
PD-L1 inhibitor, CD137 agonist
Related drugs:
2ms
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=52, Terminated, Numab Therapeutics AG | N=406 --> 52 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Feb 2024; A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Enrollment change • Trial termination • Trial primary completion date • Trispecific • Metastases
|
NM21-1480
4ms
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=406, Active, not recruiting, Numab Therapeutics AG
Trial completion date • Trispecific • Metastases
|
NM21-1480
5ms
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=406, Active, not recruiting, Numab Therapeutics AG | Recruiting --> Active, not recruiting
Enrollment closed • Trispecific • Metastases
|
NM21-1480
9ms
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin. (PubMed, Oncoimmunology)
In xenograft models, NM28-2746 exhibited significant tumor suppressing activity, which was significantly enhanced by combination therapy with NM21-1480. NM28-2746, alone or in combination with NM21-1480, may overcome shortcomings of previous MSLN-targeted immuno-oncology drugs, exhibiting enhanced discrimination of high MSLN-expressing cell activity in the presence of sMSLN.
Journal • PD(L)-1 Biomarker • IO biomarker
|
MSLN (Mesothelin)
|
MSLN expression
|
NM21-1480 • NM28-2746
Share via
